| 04.16.18 | Merck, Bristol-Myers' AACR showdown; Cyclacel's CDK2/9 blocker bounces back

Laden...

6 jaren geleden

Html
Tekst

To view this email as a web page, click here

This week's sponsor is Premier Research.
	Opportunity Knocks: Seizing the Promise of Orphan Drugs Orphan drug developers enjoy more favorable regulatory conditions today than ever. Read our white paper for tips on maximizing this opportunity. Premier Research. It's what we do. Best.

Today's Rundown

BMS' Opdivo-Yervoy combo posts big win in first-line lung cancer—but big enough to challenge Merck? Phase 1 data backs Cyclacel’s plans for CDK2/9 inhibitor Flagship’s Evelo files for $100M IPO as human testing of monoclonal microbials nears [Sponsored] It Might Be a Bumpy Ride: Why Life Sciences Companies Should Consider Embracing the New Wave of Change In a monster showing, Merck's Keytruda combo slashes lung cancer death risk by half Blueprint reports promising phase 1 data in RET-altered tumors: AACR Apitope preps Graves’ disease drug for phase 2 after positive trial Lysogene delays Sanfilippo gene therapy phase 3

Featured Story

BMS' Opdivo-Yervoy combo posts big win in first-line lung cancer—but big enough to challenge Merck?

Monday, April 16, 2018

Back in February, Bristol-Myers Squibb tallied a win for its immuno-oncology combo in first-line lung cancer. But one question still remained: Was the win big enough to keep it competitive against rivals?

This week's sponsor is Trianni.

Phase 1 data backs Cyclacel’s plans for CDK2/9 inhibitor

Monday, April 16, 2018

Just over a year ago, Cyclacel was hit by a late-stage failure in leukemia that sent its shares into a tailspin and pushed an early-stage CDK inhibitor into the spotlight as its most promising candidate. Now, that CDK drug has shown it can stabilize disease in advanced cancers and is ready to be twinned with AbbVie's leukemia drug Venclexta in phase 2.

Flagship’s Evelo files for $100M IPO as human testing of monoclonal microbials nears

Monday, April 16, 2018

Evelo Biosciences has filed for a $100 million initial public offering. The pitch to public investors comes as the Flagship Ventures’ startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.

[Sponsored] It Might Be a Bumpy Ride: Why Life Sciences Companies Should Consider Embracing the New Wave of Change

Monday, April 16, 2018

Changes in technology and geopolitics, coupled with U.S. tax reform and new financial accounting standards, are creating disruption in accounting and financial reporting for life sciences companies.

In a monster showing, Merck's Keytruda combo slashes lung cancer death risk by half

Monday, April 16, 2018

Merck's Keytruda-chemo combo is already approved in first-line lung cancer based on phase 2 data, but that FDA nod requires backup from a larger phase 3 trial—and doctors and investors have worried the data wouldn't measure up. They don't have to worry anymore.

Blueprint reports promising phase 1 data in RET-altered tumors: AACR

Monday, April 16, 2018

Blueprint Medicines presented proof-of-concept data showing its BLU-667 shrank tumors in 84% of patients with lung or thyroid cancer.

Apitope preps Graves’ disease drug for phase 2 after positive trial

Monday, April 16, 2018

Apitope has taken a step closer to developing the first new treatment option for thyroid disorder Graves’ disease in decades after posting positive results in a first-in-human trial of its ATX-GD-59 antibody.

Lysogene delays Sanfilippo gene therapy phase 3

Monday, April 16, 2018

A manufacturing delay has pushed back the start of Lysogene’s pivotal Sanfilippo syndrome trial. The gene therapy study is now due to get underway in the second half of the year.

This week's sponsor is Thermo Fisher.

Enrollment Showcase

Online Graduate Programs Designed for Your Career

Resources

[Whitepaper] MSL Outlook: What is the Future of Field Medical Affairs?

[Whitepaper] Leveraging Scientific Insights for Better Healthcare Engagement

[Whitepaper] The Future of Life Sciences Events Management

[Whitepaper] Not Like Everyone Else: Unique Challenges for Small Biopharma Companies

[Whitepaper] For Fixed-Dose Combination Manufacturing, Confidence Matters

[Whitepaper] 2018 Life Sciences Trends

[Video] So Many Choices: What’s the Right Biomanufacturing Strategy for Me?

Presented by: Patheon, part of Thermo Fisher Scientific

Patheon's Stephen Lam reviews the formidable challenges and decisions facing biopharma manufacturing executives. Watch as he shares unique insights and perspectives and demonstrates how there is really no one-size-fits-all solution in biomanufacturing, regardless of company size.

[Meeting] AACR Annual Meeting 2018

Presented by: Charles River

How do you get your oncology therapy to the clinic? The path isn’t always clear. In vitro, ex vivo, xenograft, syngeneic, PDX, humanized models, immunology considerations, safety regulations – which do you need to plan for and when?

[Whitepaper] Digitizing the Global Life Sciences Supply Chain: The Critical Role of Digital Transaction Management

[Whitepaper] Medical Device Innovation: Are You Outrunning The Competition?

[Whitepaper] Choosing the Right Solution: Improving the Site Feasibility Process

[Whitepaper] How Do Sponsors Ensure Quality in Global Clinical Trials?

Presented by: Covance

Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives.